| 000 | 01803 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517053434.0 | ||
| 264 | 0 | _c20160502 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2014.59.7302 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeumer, Jan H | |
| 245 | 0 | 0 |
_aEffect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cJan 2016 |
||
| 300 |
_a110-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers _xmetabolism |
| 650 | 0 | 4 |
_aClinical Trials, Phase I as Topic _xstatistics & numerical data |
| 650 | 0 | 4 |
_aCreatinine _xmetabolism |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aRenal Insufficiency, Chronic _xblood |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aDing, Fei | |
| 700 | 1 | _aTawbi, Hussein | |
| 700 | 1 | _aLin, Yan | |
| 700 | 1 | _aViluh, Diana | |
| 700 | 1 | _aChatterjee, Indrani | |
| 700 | 1 | _aRinker, Matthew | |
| 700 | 1 | _aChow, Selina L | |
| 700 | 1 | _aIvy, S Percy | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 34 _gno. 2 _gp. 110-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2014.59.7302 _zAvailable from publisher's website |
| 999 |
_c25282088 _d25282088 |
||